|

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

RECRUITINGSponsored by St. Jude Children's Research Hospital
Actively Recruiting
SponsorSt. Jude Children's Research Hospital
Started2026-01-20
Est. completion2027-03
Eligibility
Healthy vol.Accepted
Locations2 sites

Summary

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).

  * Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
* Age ≤ 30 years at CAR T cell infusion.

Exclusion Criteria:

* Active malignancy other than the disease under study.
* Planned consolidative HSCT within 3 months post CAR T cell infusion.
* Received or planned additional disease directed therapy post CAR T cell infusion.
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Conditions4

B-ALLCancerHematologic MalignancySolid Tumor

Locations2 sites

Tennessee

1 site
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
Rebecca Epperly, MD866-278-5833referralinfo@stjude.org

Wisconsin

1 site
Children's Hospital of Wisconsin.
Milwaukee, Wisconsin, 53226
Amy Moskop, MD414-955-4142amoskop@mcw.edu

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.